Medicinal Chemistry Services
- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
Discovery PK and Toxicology
As Chief Financial Officer (CFO), Joe (Yifeng) Gao has the primary responsibility for planning, implementing, managing and controlling all financial-related activities for Frontage.
CABS workshop "Preclinical and Early Phase Development of Biologics and Small Molecules" sponsored by Frontage Laboratories, Inc., was successfully held on December 11th, 2018 at DoubleTree Hotel in Burlingame, California. The workshop featured four presentations by leading experts in areas of preclinical and early stage development of biologics and small molecule therapeutics and a lively panel discussion on hot topics and emerging trends in biologics and small molecule drug development.
Exton, PA, July 10, 2018: Frontage Laboratories, Inc. has been named as a 2018 CRO Leadership Awards recipient by Life Science Leader magazine. The publication annually asks pharmaceutical and biopharmaceutical companies to rate the capability and performance of contract research organizations.
Dr. Song Li, Founder and CEO of Frontage Laboratories, Inc., has been awarded the Entrepreneur Of The Year®Award for 2018.
Dr. Song Li, Founder and CEO of Frontage Laboratories, Inc., has been awarded the Healthcare CEO of the Year Enterprise Award for 2018.
Frontage Laboratories, Inc., is pleased to announce the appointment of Dr. Hugh Davis as Chief Business Officer (CBO), in charge of Business Development, Sales, Marketing and Strategic Partnerships.
Frontage Laboratories, Inc., a global CRO with headquarters in Exton, Pennsylvania, announces the acquisition of Concord Biosciences, formerly known as Ricerca Biosciences, LLC, a preclinical CRO located near Cleveland, Ohio. Founded in 1986, Concord Bio supports the pharmaceutical, agricultural, chemical, and animal health industries with Drug Safety, Metabolism, Bioanalytical, Residue, and Environmental Fate studies.
Dr. Song Li, Founder and CEO of Frontage Laboratories, said, “We have committed to build a global CRO company with integrated services. The acquisition of Concord Biosciences is a significant step toward reaching our goal. The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization. Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry.”.
Frontage Laboratories, Inc., a full-service early-stage CRO with locations in the USA and China, has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, its full service offerings include DMPK, bioanalysis, analytical testing, product development and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health pharmaceutical companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Frontage has successfully enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets. For more information, visit https://www.frontagelab.com/
About Concord Biosciences:
Founded in 1986, Concord is a contract research organization that supports the pharmaceutical, agricultural, and animal health industries. Our comprehensive, integrated suite of services help our clients meet their regulatory requirements and internal development goals. Located on a 20-acre campus in Concord, Ohio, our expansive facilities allow for Concord to operate on the scale of a large CRO, while offering the nimbleness of a small CRO. Concord is relentless in its pursuit of client service and adding value to client situations through accelerating timelines and providing expert collaboration. For more information, visit http://www.concordbio.com/
To meet the growing demand for laboratory and clinical services solutions in the Mid-Atlantic Region, Frontage Laboratories, Inc., a global CRO with headquarters in Exton, PA, has opened a new branch office located in 101 Carnegie Center in Princeton, New Jersey.
Frontage Laboratories, a leading quality drug development partner for many of the world's best pharmaceutical, biotechnology & biologics companies, is pleased to announce the appointment of Dr. Luca C. Matassa to the position of Vice President, Bioanalytical Operations & Client Services, Frontage Laboratories Exton, Pa. “Adding Dr. Matassa’s extensive bioanalytical knowledge, vision, leadership and process improvement experience to Frontages present and future capabilities is a winning partnership for success for our organization and our clients.
Dr. Matassa joins Frontage with over twenty-five years of scientific, operations, process improvement and business experience in bioanalysis in the Contract Research Organization (CRO) industry and in Drug Development in the pharmaceutical company, which will be a great addition to the currently growing bioanalytical and Biologics team in Frontage”, John Lin, EVP, Bioanalytical and Biologics at Frontage commented.
Since 2014, Dr Matassa served as VP of Bioanalytical & then VP of Process Development at QPS, LLC De.
From 2010 to 2013, Dr Matassa served as a Consultant at Eisai Inc. in Woodcliff Lake NJ in Clinical Bioanalytical study outsourcing as well as Senior Lab Director at Alta-Intertek, EDH Ca. Luca was at Tandem Labs from 2004 to 2010, initially in the role of Bioanalytical Lab Director in Salt Lake City, Utah, then as General Manager of Tandem Labs Bioanalytical Operations West Trenton, New Jersey.
He was previously responsible for the establishment and operations of a high-throughput bioanalytical laboratory for Covance Bioanalytical Services, LLC as Associate Director of Operations in Indianapolis, Indiana from 2000 to 2004. From 1989 to 2000, Dr. Matassa served in successive positions at Maxxam Analytics Inc. in Canada including Manager of the Bioanalytical Department. Dr. Matassa established the first Sciex LC/MS/MS based contract bioanalytical laboratory in Canada. During his career he has published over 50 scientific papers and posters primarily focused on bioanalytical laboratory processes and the use of LC/MS/MS for quantitative bioanalysis for both small and large molecules. Dr. Matassa earned his Doctorate in Organic Chemistry from the University of Windsor, Ontario, Canada in 1989.